INTS: Intensity Therapeutics, Inc. Stock

by  •  • Comments Off on INTS: Intensity Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 52.78
Enterprise Value ($M) 44.23
Book Value ($M) 13.16
Book Value / Share 0.96
Price / Book 4.01
NCAV ($M) 11.33
NCAV / Share 0.83
Price / NCAV 4.66

Profitability (mra)
Return on Invested Capital (ROIC) -0.79
Return on Assets (ROA) -11.08
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 3.91
Current Ratio 3.91

Balance Sheet (mrq) ($M)
Current Assets 15.46
Assets 17.30
Liabilities 4.13
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -8.32
Net Income -10.54

Cash Flow Statement (mra) ($M)
Cash From Operations -7.21
Cash from Investing -6.02
Cash from Financing 20.47

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G Bender Lewis H 16.10

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-14 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark one) x ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSITION REPORT PURSUANT
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT
2023-08-14 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRAN
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURS

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 1,297 4,486 28.91
2024-05-02 177 292 60.62
2024-05-01 742 570 130.18
2024-04-30 270 788 34.26

(click for more detail)

Similar Companies
INKT – MiNK Therapeutics, Inc. INM – InMed Pharmaceuticals Inc.
INMB – INmune Bio, Inc. ITRM – Iterum Therapeutics plc
JAGX – Jaguar Health, Inc.


Financial data and stock pages provided by
Fintel.io